格林威治生命科学促进乳腺癌免疫疗法GP2,完成初步制造阶段。 Greenwich LifeSciences advances breast cancer immunotherapy GP2, completing initial manufacturing milestones.

格林威治生命科学公司在生产GP2方面取得了进展,GP2是其乳腺癌免疫疗法GLSI-100的活性成分,2023年生产了三个商业批量,2024年完成了三个瓶装地中的第一个。 Greenwich LifeSciences has made progress in manufacturing GP2, the active ingredient in its breast cancer immunotherapy GLSI-100, with three commercial lots produced in 2023 and the first of three vial-filled lots completed in 2024. 该公司的目标是在进行第三阶段试验的同时再完成两个批量,为潜在的林业发展局和EMA的批准和商业销售做准备。 The company aims to finish two more lots while conducting a Phase III trial, preparing for potential FDA and EMA approval and commercial sales. 它们还致力于完善GLSI-100的制造和管理过程。 They are also working on refining the manufacturing and administration processes of GLSI-100.